共 22 条
[1]
Coloma PM(2013)Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? Drug Safety 36 183-197
[2]
Trifirò G(2014)Oversight and evidence in stem cell innovation: an examination of international guidelines Law, Innovation and Technology 6 30-50
[3]
Patadia V(2015)Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review Circulation Cardiovascular Quality and Outcomes 8 47-55
[4]
Sturkenboom M(2014)Review of the quality of observational studies of the association between rosiglitazone and acute myocardial infarction Journal of Population Therapeutics and Clinical Pharmacology 21 e214-e232
[5]
Lysaght T(2018)Vaginal mesh procedures need compulsory register, says royal college BMJ 360 k586-846
[6]
Melloni C(2007)The rosiglitazone story—lessons from an FDA Advisory Committee meeting New England Journal of Medicine 357 844-806
[7]
Washam JB(2010)Revisiting the rosiglitazone story—lessons learned New England Journal of Medicine 363 803-227
[8]
Jones WS(2015)Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes? Pharmacoepidemiology and Drug Safety 24 223-undefined
[9]
Halim SA(2018)Government’s vaginal mesh audit does not go far enough, say campaigners BMJ 361 k1701-undefined
[10]
Hasselblad V(undefined)undefined undefined undefined undefined-undefined